The Technical Analyst
Sunesis Pharmaceuticals [VIRX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Sunesis Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.75% $0.857
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 33.64 mill |
| EPS: | -1.320 |
| P/E: | -0.650 |
| Earnings Date: | May 05, 2024 |
| SharesOutstanding: | 39.27 mill |
| Avg Daily Volume: | 0.116 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.650 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.11x |
| Company: PE -0.650 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.343 (-140.01%) $-1.199 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.762 - 0.962 ( +/- 11.61%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-20 | Burcar Melody | Sell | 80 000 | Stock Option (Right to Buy) |
| 2024-03-20 | Burcar Melody | Sell | 47 500 | Stock Option (Right to Buy) |
| 2024-03-20 | Burcar Melody | Sell | 33 250 | Stock Option (Right to Buy) |
| 2024-03-20 | Burcar Melody | Sell | 100 000 | Stock Option (Right to Buy) |
| 2024-03-12 | Rothera Mark | Buy | 475 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 67.99 |
| Last 97 transactions |
| Buy: 4 797 715 | Sell: 606 024 |
Forecast:
16:00 - $0.862
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.862
Forecast 2: 16:00 - $0.862
Forecast 3: 16:00 - $0.862
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.857 (-5.75% ) |
| Volume | 0.0525 mill |
| Avg. Vol. | 0.116 mill |
| % of Avg. Vol | 45.45 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VIRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VIRX
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-15 08:00:00 - Press Release
Viracta Therapeutics Announces Positive Topline Nana-val Results From Stage 1 Of The Naval-1 Trial In Patients With Relapsed Or Refractory Epstein-barr Virus-positive (ebv+) Peripheral T-cell Lymphoma
- patients in the nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in the intent-to-treat population (71% and 29% in the efficacy-evaluable population) with a generally manageable safety profile -
2024-04-01 08:30:00 - Press Release
Viracta Therapeutics To Present Topline Nana-val Results From Stage 1 Of The Naval-1 Trial At The 2024 Annual Congress Of The Hematology Society Of Taiwan
The oral presentation will focus on topline stage 1 data from both arms of the relapsed or refractory ebv+ peripheral t-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy [n=10] or to nanatinostat in combination with valganciclovir [nana-val, n=10]), with an aim to clearly delineate the differentiation of nana-val's ‘kick and kill' mechanism of action the oral presentation will focus on topline stage 1 data from both arms of the relapsed or refractory ebv+ peripheral t-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy [n=10] or to nanatinostat in combination with valganciclovir [nana-val, n=10]), with an aim to clearly delineate the differentiation of nana-val's ‘kick and kill' mechanism of action
2024-03-07 16:05:00 - Press Release
Viracta Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
Completed stage 2 enrollment in the naval-1 trial of nana-val in patients with relapsed or refractory ebv + peripheral t-cell lymphoma supporting its speed to market strategy; topline results from stage 1 of the study expected in the second quarter of 2024
2024-02-29 08:00:00 - Press Release
Viracta Therapeutics Announces Completion Of Second-stage Enrollment Into The Peripheral T-cell Lymphoma Cohort Of The Naval-1 Trial
Accelerated pace of enrollment supports speed to market strategy topline results from stage 1 expected to be presented in the second quarter of 2024 followed by stage 2 data in the third quarter of 2024 san diego, feb. 29, 2024 (globe newswire) -- viracta therapeutics, inc. (nasdaq: virx), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its lead development program, nana-val (nanatinostat in combination with valganciclovir), a first-in-class, all-oral investigational therapy targeting epstein-barr virus (ebv)-associated cancers, has completed stage 2 enrollment into the relapsed or refractory (r/r) epstein-barr virus-positive (ebv+) peripheral t-cell lymphoma (ptcl) cohort of the naval-1 trial...
2024-02-06 16:05:00 - Press Release
Viracta Therapeutics To Present At The Oppenheimer 34th Annual Healthcare Life Sciences Conference
San diego, feb. 06, 2024 (globe newswire) -- viracta therapeutics, inc. (nasdaq: virx), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that mark rothera, its president and chief executive officer, and darrel p. cohen, m.d., ph.d., its chief medical officer, are scheduled to participate in a virtual fireside chat at the oppenheimer 34th annual healthcare life sciences conference on tuesday, february 13, 2024, at 9:00 a.m. pt/12:00 p.m. et.
Latest News
2024-04-01 08:30:00 - GlobeNewsWire
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy [n=10] or to nanatinostat in combination with valganciclovir [Nana-val, n=10]), with an aim to clearly delineate the differentiation of Nana-val's ‘Kick and Kill' mechanism of action The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy [n=10] or to nanatinostat in combination with valganciclovir [Nana-val, n=10]), with an aim to clearly delineate the differentiation of Nana-val's ‘Kick and Kill' mechanism of action
2024-02-06 16:05:00 - GlobeNewsWire
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Darrel P. Cohen, M.D., Ph.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 9:00 a.m. PT/12:00 p.m. ET.
2023-11-07 16:15:00 - GlobeNewsWire
Viracta Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Company's Management will participate in upcoming investor conferences in November.
2023-05-31 16:15:00 - GlobeNewsWire
Viracta Therapeutics to Present at the Jefferies Healthcare Conference
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 3:00 p.m. EDT.
2023-05-11 16:05:00 - GlobeNewsWire
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Dan Chevallard, its Chief Operating Officer and Chief Financial Officer, are scheduled to participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 4:05 p.m. EDT.
2023-04-19 16:30:00 - GlobeNewsWire
Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 12:00 p.m. ET.
2023-03-08 16:05:00 - GlobeNewsWire
Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the 33rd Annual Oppenheimer Healthcare Conference on Wednesday, March 15, 2023, at 12:00 p.m. ET.
2023-02-07 16:05:00 - GlobeNewsWire
Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, is scheduled to present at the virtual 2023 SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 1:00 p.m. ET.
2022-09-08 14:18:09 - Zacks Investment Research
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma
Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.
2022-07-11 09:19:11 - Zacks Investment Research
Here's Why Viracta Therapeutics (VIRX) is Up So Far This Year
Viracta Therapeutics' (VIRX) Nana-val is being evaluated in multiple clinical studies in various subtypes of EBV-associated cancers.